H.B. No. 4014 proposes a study by the Health and Human Services Commission on the use of psychedelic therapies, specifically MDMA, psilocybin, and ketamine, for treating conditions such as post-traumatic stress disorder (PTSD) and depression. The commission will collaborate with Baylor College of Medicine and the Center for Psychedelic Research and Therapy at Dell Medical School to review clinical trials, current literature, and FDA actions regarding these therapies. The study will also evaluate treatment guidelines and patient access to ensure that, following FDA approval, patients can access these therapies effectively.

The bill outlines that the commission may seek federal funds and donations to finance the study and mandates a report to be submitted by December 1, 2026, detailing the study's findings and recommendations for legislative action. Additionally, the implementation of the bill's provisions is contingent upon specific appropriations by the legislature, and the act is set to expire on September 1, 2027, with an effective date of September 1, 2025.